Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 379

1.

Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.

Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1939-44. doi: 10.1073/pnas.1317350111. Epub 2014 Jan 2. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6115. Retraction in: Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2738.

2.

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM.

J Virol. 2017 Feb 14;91(5). pii: e02041-16. doi: 10.1128/JVI.02041-16. Print 2017 Mar 1.

PMID:
28031369
3.

Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.

Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE Jr, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS.

J Virol. 2016 Apr 29;90(10):5090-7. doi: 10.1128/JVI.00155-16. Print 2016 May 15.

4.

Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.

Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr.

J Virol. 2014 Nov;88(21):12233-41. doi: 10.1128/JVI.00247-14. Epub 2014 Aug 6.

5.

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. doi: 10.1073/pnas.1200566109. Epub 2012 Apr 12.

6.

Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.

Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM.

Virology. 2009 Sep 15;392(1):103-13. doi: 10.1016/j.virol.2009.06.037. Epub 2009 Jul 24.

7.

Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.

Zidane N, Dussart P, Bremand L, Bedouelle H.

BMC Infect Dis. 2013 Jul 1;13:302. doi: 10.1186/1471-2334-13-302.

8.

Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.

Briggs CM, Smith KM, Piper A, Huitt E, Spears CJ, Quiles M, Ribeiro M, Thomas ME, Brown DT, Hernandez R.

J Virol. 2014 Jun;88(12):6729-42. doi: 10.1128/JVI.00541-14. Epub 2014 Apr 2.

9.

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761. Epub 2013 Dec 5.

11.

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.

Poddar A, Ramasamy V, Shukla R, Rajpoot RK, Arora U, Jain SK, Swaminathan S, Khanna N.

BMC Biotechnol. 2016 Jun 14;16(1):50. doi: 10.1186/s12896-016-0280-y.

12.

Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS.

J Virol. 2010 Oct;84(20):10630-43. doi: 10.1128/JVI.01190-10. Epub 2010 Aug 11.

13.

A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.

Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE Jr, de Silva AM, Baric RS.

MBio. 2015 Oct 13;6(5):e01461-15. doi: 10.1128/mBio.01461-15.

14.

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.

15.

Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.

Li XQ, Qiu LW, Chen Y, Wen K, Cai JP, Chen J, Pan YX, Li J, Hu DM, Huang YF, Liu LD, Ding XX, Guo YH, Che XY.

J Gen Virol. 2013 Oct;94(Pt 10):2191-201. doi: 10.1099/vir.0.055178-0. Epub 2013 Jul 12.

PMID:
23851440
16.

Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.

Messer WB, Yount B, Hacker KE, Donaldson EF, Huynh JP, de Silva AM, Baric RS.

PLoS Negl Trop Dis. 2012;6(2):e1486. doi: 10.1371/journal.pntd.0001486. Epub 2012 Feb 28.

17.

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.

Priyamvada L, Cho A, Onlamoon N, Zheng NY, Huang M, Kovalenkov Y, Chokephaibulkit K, Angkasekwinai N, Pattanapanyasat K, Ahmed R, Wilson PC, Wrammert J.

J Virol. 2016 May 27;90(12):5574-85. doi: 10.1128/JVI.03203-15. Print 2016 Jun 15.

18.

Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.

Galula JU, Shen WF, Chuang ST, Chang GJ, Chao DY.

J Virol. 2014 Sep;88(18):10813-30. doi: 10.1128/JVI.00810-14. Epub 2014 Jul 9.

19.

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK.

J Virol. 2013 Dec;87(23):12562-75. doi: 10.1128/JVI.00871-13. Epub 2013 Sep 11.

20.

Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM.

J Virol. 2012 Apr;86(7):4019-23. doi: 10.1128/JVI.06871-11. Epub 2012 Jan 25.

Supplemental Content

Support Center